Intravenous rFVIIa Administered for Hemorrhage Control in Hypothermic Coagulopathic Swine with Grade V Liver Injuries

Martinowitz, Uri; Holcomb, John B.; Pusateri, Anthony E.; Stein, Michael D.; Onaca, Nicholas; Freidman, Mony; Macaitis, Joseph; Castel, David; Hedner, Ulla; Hess, John R.

doi:10.1097/00005373-200104000-00021

Cited by 170 publications

(107 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Animal models have shown that rFVIIa effectively decreases blood loss at trauma [45] and also increased evidence of its efficacy at trauma patients was found [46,47]. In a multicentre, double-blind, prospective, randomized, placebo-controlled trial rFVIIa was shown to be effective and safe in reducing PRBCs transfusion especially in blunt trauma patients, as well as showing a good safety profile [48] when used as an adjunct to trauma care [49].…”

Section: Optimal Treatment Of Critical Bleeding In Traumamentioning

confidence: 99%

Management of Critical Bleeding in Trauma Patients: Between Recommendations and Reality

Shosholcheva¹,

Јankulovski²,

Кузмановска³

et al. 2015

JACCOA

View full text Add to dashboard Cite

Section: Optimal Treatment Of Critical Bleeding In Traumamentioning

confidence: 99%

Management of Critical Bleeding in Trauma Patients: Between Recommendations and Reality

Shosholcheva¹,

Јankulovski²,

Кузмановска³

et al. 2015

JACCOA

View full text Add to dashboard Cite

“…Finding an intravenous treatment that could assist endogenous clotting mechanisms is therefore a major mission for military researchers. The possibility that hemostatic agents might be useful in reducing blood loss following traumatic injury has received new impetus from the recent use of rFVIIa in both animal models of traumatic injury [8][9][10][11][12][13][14] and in human patients who have suffered traumatic injury [15][16][17]. Although rFVIIa holds promise for such indications, it is also very expensive and is not yet approved for a trauma indication.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of FDA-approved hemostatic drugs to improve survival and reduce bleeding in rat models of uncontrolled hemorrhage

et al. 2006

Self Cite

View full text Add to dashboard Cite

“…It does not appear that rFVIIa induces a generalized hypercoagulability but that its action is limited to the site of injury [5,[11][12][13]. Preliminary results in both animal and human subjects indicate that rVIIa may also play a beneficial role in the treatment of hemorrhage control in cases of trauma [13][14][15][16][17][18][19], although this is not a universal finding [20][21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Testing of Intravenous Hemostatic Agents in a Novel Swine Model of Bleeding: Preliminary Results With FXa-PCPs

Ryan¹,

Dorfman²,

Jenny³

et al. 2005

View full text Add to dashboard Cite

The public reporting burden for this collection of information is estimated to average 1 hour por reaponse. including the time for reviewing instructions. aearching existing data sources, gatharin9 and maintaining the data needed. and completing and reviewing the collection of Information. Send comments regarding this burden estimate or any other aspect of thia collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reaports 10704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Rleapondenta should be aware that notwithstanding any other proviaion of law, no person shall be subject to any penalty for failing to comply with a collection of information if it doea not diaplay a currently valid 0M8 control number. PLEASE DO NOT RETURN YOUR PERFORMING ORGANIZATION NAME(S) AND ADORESSDESS). PERFORMING ORGANIZATION SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITORS ACRONYM(S)U ABSTRACTFinding an intravenous treatment that could assist endogenous clotting mechanisms is a major mission for military researchers. Herein, we report preliminary data on the efficacy of mixtures of highly purified blood coagulation factors (FVIIa and FXa) and phospholipids vesicles (PCPS) to reduce traumatic bleeding. A novel swine model was developed in which 1) bleeding times (BT) and coagulation function could be ascertained following multiple doses of drug administration; and, 2) an exsanguinating injury could subsequently be performed in the same animal, yielding screening information as to the effects of drug pretreatment of blood loss and survival. FXa-PCPS failed to reduce BT or enhance coagulation function and a dose-dependent hypotensive response. FVIIa-PCPS yielded no data suggestive of the profound potentiation of FVIIa activity by PCPS observed in previous in vitro testing.Further study of these drugs for the use of traumatic hemorrhage is not warranted. SUBJECT TERMS

show abstract

Intravenous rFVIIa Administered for Hemorrhage Control in Hypothermic Coagulopathic Swine with Grade V Liver Injuries

Abstract: rFVIIa reduced blood loss and restored abnormal coagulation function when used in conjunction with liver packing in hypothermic and coagulopathic swine. No adverse effects were identified.

Cited by 170 publications

References 63 publications

Management of Critical Bleeding in Trauma Patients: Between Recommendations and Reality

Management of Critical Bleeding in Trauma Patients: Between Recommendations and Reality

Efficacy of FDA-approved hemostatic drugs to improve survival and reduce bleeding in rat models of uncontrolled hemorrhage

Testing of Intravenous Hemostatic Agents in a Novel Swine Model of Bleeding: Preliminary Results With FXa-PCPs

Contact Info

Product

Resources

About